Add Formweb to your mobile device
Following is a P and T Committee update (from the February 27th meeting). Starting date for specific programs is 5 March 2018, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
|
aprepitant liposomal (Cinvanti) injection |
Formulary, Restricted |
Civanti was restricted to use by Oncology for chemotherapy induced nausea and vomiting (CINV). Civanti may be administered IV push. |
|
rolapitant (Varubi) IV and fosaprepitant (Emend) IV Update |
Formulary, Restricted Therapeutic Interchange Approved |
Orders for Varubi IV and Emend IV for CINV will be interchanged to Civanti following the approved dosage nomogram. Varubi IV and Emend IV will be dispensed as written if no substitution is specified. Emend PO will continue to be available for post-operative nausea and vomiting. |
|
spironolactone (Carospir) suspension |
Formulary |
A 1 mg: 1 mg conversion for tablets to Carospir was approved in adult patients to avoid crushing tablets and facilitate enteral administration. The pharmacist will contact MD about dosage conversion from tablet to suspension in pediatric patients. |
|
triptorelin pamoate (Triptodur) injection |
Non-Formulary |
Defer initiation until after hospital discharge. |
|
levodopa powder |
Formulary, Restricted |
Restricted to use in pediatrics for growth hormone deficiency testing. |
|
dexmethylphenidate (Focalin XR) extended release Interchange Update |
Interchange Update Approved |
Focalin XR remains non-formulary. Three new formulation strengths were added to the interchange program for adult patients. |
|
amphetamine sulfate (Adzenys XR-ODT) extended-release ODT |
Non-Formulary Interchange Approved for Adults |
Automatic interchange to Adderall XR approve for adults. For pediatrics, contact MD for any change in drug product. Patient may use own supply if necessary during admission. |
|
Glycerin Enemas in Neonates |
Approved use in Neonate Population |
Benefits determined to outweigh the potential risk associated with glycerin use in this population. |
|
Formulary Interchange Approved |
AquADEK chewable tablets and liquid products to replace ADEKs formulations which have been manufacturer discontinued. |
|
|
inFLIXimab Usage Update – Pediatrics |
Formulary, Restricted Expanded use in Pediatrics Approved |
Approved for use in Kawasaki Disease. |
|
Proton Pump Inhibitor in Pediatrics Update |
esomeprazole (Nexium) to serve as formulary workhorse for pediatric liquid/tube administration. Interchange Approved |
Automatic interchange to esomeprazole granules for pediatric patients requiring liquid or tube administration of a PPI following age-based dosing recommendations. The prescribing physician will be contacted prior to an interchange if, patient is < 1 month of age, the dose exceeds 3.5 mg/kg/day, or PPI was prescribed more than once daily. |